PMID- 26076841
OWN - NLM
STAT- MEDLINE
DCOM- 20160414
LR  - 20150616
IS  - 1532-2688 (Electronic)
IS  - 1059-1311 (Linking)
VI  - 29
DP  - 2015 Jul
TI  - The anti-depression effect of Xylaria nigripes in patients with epilepsy: A 
      multicenter randomized double-blind study.
PG  - 26-33
LID - S1059-1311(15)00084-9 [pii]
LID - 10.1016/j.seizure.2015.03.014 [doi]
AB  - PURPOSE: The comorbidity of depression in patients with epilepsy is common and 
      treatment is still controversial. This pilot study was aimed at evaluating the 
      efficacy and safety of Xylaria nigripes for treating depressive symptoms in 
      patients with epilepsy during 12 weeks of treatment. METHODS: A multicenter, 
      double-blind, placebo-controlled, randomized superiority study was performed. A 
      total of 104 patients with epilepsy who fulfilled the study criteria were 
      randomized 1:1 to receive Xylaria nigripes (the Wu Ling group) or placebo (the 
      placebo group) treatment in the 12-week period of study. The participants were 
      visited on weeks 0, 2, 4, 8, and 12 of the treatment course. RESULTS: Eighty-one 
      patients finished all of the visits. The primary efficacy endpoint in this study 
      was the total effective rate for depression, which was significantly greater in 
      the Wu Ling group (51.3%, n=39) than in the placebo group (35.7%, n=42, 
      0.51-0.36=0.15, 95% CI -0.06 to 0.37, U=2.83, P=0.002) after 12 weeks of 
      treatment. No differences in seizure frequency or changes in severity were found 
      between the Wu Ling and the placebo groups. In addition, the quality of life and 
      seizure worry subscale scores in patients with epilepsy were also improved more 
      notably in the Wu Ling group than in the placebo group (P<0.05). Most of the 
      adverse effects (AEs) in this study were mild and had no differences between the 
      Wu Ling and the placebo groups. CONCLUSION: Xylaria nigripes could alleviate 
      depressive symptoms within 12 weeks treatment and was well tolerated in patients 
      with epilepsy.
CI  - Copyright (c) 2015 British Epilepsy Association. Published by Elsevier Ltd. All 
      rights reserved.
FAU - Peng, Wei-Feng
AU  - Peng WF
AD  - Department of Neurology, Zhongshan Hospital, Fudan University, Shanghai, China.
FAU - Wang, Xin
AU  - Wang X
AD  - Department of Neurology, Zhongshan Hospital, Fudan University, Shanghai, China; 
      The State Key Laboratory of Medical Neurobiology, The Institutes of Brain Science 
      and the Collaborative Innovation Center for Brain Science, Fudan University, 
      Shanghai, China. Electronic address: wang.xin@zs-hospital.sh.cn.
FAU - Hong, Zhen
AU  - Hong Z
AD  - Department of Neurology, Huashan Hospital, Fudan University, Shanghai, China.
FAU - Zhu, Guo-Xing
AU  - Zhu GX
AD  - Department of Neurology, Huashan Hospital, Fudan University, Shanghai, China.
FAU - Li, Bing-Mei
AU  - Li BM
AD  - Epilepsy Center of the Second Affiliated Hospital of Guangzhou Medical 
      University, Guangdong Province, China.
FAU - Li, Ze
AU  - Li Z
AD  - Department of Neurology, The First Municipal Hospital of Guangzhou, Guangdong 
      Province, China.
FAU - Ding, Mei-Ping
AU  - Ding MP
AD  - Department of Neurology, The Second Affiliated Hospital of Zhejiang University 
      School of Medicine, Hangzhou, Zhejiang Province, China.
FAU - Geng, Zhi
AU  - Geng Z
AD  - Department of Neurology, The Sixth People's Hospital of Shanghai Jiaotong 
      University, Shanghai, China.
FAU - Jin, Zheng
AU  - Jin Z
AD  - Department of Neurology, The Fifth People's Hospital, Fudan University, Shanghai, 
      China.
FAU - Miao, Ling
AU  - Miao L
AD  - Department of Neurology, Renji Hospital, Shanghai Jiaotong University, Shanghai, 
      China.
FAU - Wu, Li-Wen
AU  - Wu LW
AD  - Department of Neurology, Peking Union Medical College Hospital, Beijing, China.
FAU - Zhan, Shao-Kang
AU  - Zhan SK
AD  - Institute of Statistics and Public Health, Shanghai Medical College, Fudan 
      University, China.
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20150326
PL  - England
TA  - Seizure
JT  - Seizure
JID - 9306979
RN  - 0 (Antidepressive Agents)
RN  - 0 (Drugs, Chinese Herbal)
RN  - 0 (wuling)
SB  - IM
MH  - Adult
MH  - Antidepressive Agents/adverse effects/*therapeutic use
MH  - Comorbidity
MH  - Depressive Disorder/*complications/*drug therapy/epidemiology
MH  - Double-Blind Method
MH  - Drugs, Chinese Herbal/adverse effects/*therapeutic use
MH  - Epilepsy/*complications/epidemiology
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Psychiatric Status Rating Scales
MH  - Quality of Life
MH  - Seizures/complications/epidemiology
MH  - Sleep/drug effects
MH  - Time Factors
MH  - Treatment Outcome
OTO - NOTNLM
OT  - Comorbidity
OT  - Depression
OT  - Epilepsy
OT  - Randomized clinical trial
OT  - Xylaria nigripes
EDAT- 2015/06/17 06:00
MHDA- 2016/04/15 06:00
CRDT- 2015/06/17 06:00
PHST- 2015/01/05 00:00 [received]
PHST- 2015/03/16 00:00 [revised]
PHST- 2015/03/19 00:00 [accepted]
PHST- 2015/06/17 06:00 [entrez]
PHST- 2015/06/17 06:00 [pubmed]
PHST- 2016/04/15 06:00 [medline]
AID - S1059-1311(15)00084-9 [pii]
AID - 10.1016/j.seizure.2015.03.014 [doi]
PST - ppublish
SO  - Seizure. 2015 Jul;29:26-33. doi: 10.1016/j.seizure.2015.03.014. Epub 2015 Mar 26.